Tag

comunicati- Pagina 24

Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA “Best Start-Up” Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)

martedì, 13 Ottobre 2026
SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes  This second consecutive nomination places our company and

Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA “Best Start-Up” Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)

martedì, 13 Ottobre 2026
SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes  This second consecutive nomination places our company and
1 … 22 23 24 25 26 … 665